Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of common stock (the “Option Award”) and 42,388 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The Option Award and RSU Award were each granted as of September 28, 2026 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas’ stock incentive plan.

The option has a 10-year term and an exercise price of $7.51 per share, which is equal to the closing price per share of Arvinas’ common stock on the grant date. The Option Award will vest over four years, with 25% of the original number of shares underlying the Option Award vesting on the one-year anniversary of the employee’s start date and 1/48th of the original number of shares vesting monthly thereafter, and the RSU Award will vest in four equal installments on each one-year anniversary of the employee’s start date until the fourth anniversary of the start date, in each case subject to the employee’s continued service as an employee of, or other service provider to, Arvinas through the applicable vesting dates.